{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-22-000092","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2022-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.679331+00:00","generated_at":"2026-06-23T03:12:07.416471+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MacroGenics and Gilead sign $60M upfront option deal for MGD024 and two bispecific programs","bullets":["Upfront $60M from Gilead; potential milestones up to $1.7B for MGD024 and two research programs.","Gilead gets exclusive option to license MGD024 (Phase 1 CD123×CD3 DART) for AML and MDS.","MacroGenics to continue Phase 1 study; Gilead may exercise option at predefined decision points.","Tiered double-digit royalties on MGD024 net sales; flat royalties on products from two research programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-22-000092","json":"https://secwatch.observer/filing/0001125345-22-000092.json","markdown":"https://secwatch.observer/filing/0001125345-22-000092.md","text":"https://secwatch.observer/filing/0001125345-22-000092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000092/0001125345-22-000092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534522000092/mgnx-20221017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T03:12:07.416471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}